Statistics

GWPharma - Welcome

www.gwpharmaceuticals.org/

news2Introducing GW PharmaceuticalsDiscover more about GW...Meeting patients' needsPatient information can be found here....World leading scienceMore about ...

Gwpharmaceuticals.org

Conversion Technology Metas Server

Gwpharmaceuticals.org is hosted in United Kingdom / New Malden . Gwpharmaceuticals.org doesn't use HTTPS protocol. Number of used technologies: 6. First technologies: CSS, Cufon, Html, Number of used javascripts: 11. First javascripts: Common.js, Common2.js, Functions.js, Number of used analytics tools: 1. First analytics tools: Google Analytics, Its server type is: Microsoft-IIS/7.5.

Technologies in use by Gwpharmaceuticals.org

Technology

Number of occurences: 6

CSS
Cufon
Html
Javascript
jQuery Cycle
Php

Javascripts

Number of occurences: 11

common.js
common2.js
functions.js
jquery-1.5.1.min.js
cufon-yui.js
AvantGardeITCbyBT_Medium_500.font.js
jquery.min.js
jquery.cycle.all.js
jquery.easing.1.3.js
slides.min.jquery.js

Analytics

Number of occurences: 1

Google Analytics

Server Type

Microsoft-IIS/7.5

Conversion rate optimization
Clickable call number	Not founded!
Conversion form (contact form, subcriber)	Not founded!
Clickable email	Not founded!
CTA (call to action) button	Founded!
List	Founded!
Image	Not founded!
Enhancement	Not founded!
Responsive website	Not founded!
Facebook sharing	Not founded!
Google+ sharing	Not founded!
Twitter sharing	Not founded!
Linkedin sharing	Not founded!
Blog on the webiste	Not founded!

HTTPS (SSL) - Gwpharmaceuticals.org

Missing HTTPS protocol.

Meta - Gwpharmaceuticals.org

Number of occurences: 3

Name:
Content: text/html; charset=UTF-8
Name: keywords
Content: news2Introducing GW PharmaceuticalsDiscover more about GW...Meeting patients' needsPatient information can be found here....World leading scienceMore about our scientific collaborations...A valuable pipelineOur areas of therapeutic interest...An exciting futureLearn more about our future opportunities...http://apps.shareholder.com/irxml/irxml.aspx?COMPANYID=AMDA-1TW341&PIN=510645233&FUNCTION=StockQuote&OUTPUT=xml&TICKER=GWPHhttp://ir2.flife.de/data/gwpharma/xml.phpGW Pharmaceuticals plc Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising $289.8 Million on the NASDAQ Global Market and Full Exercise of Underwriterâ€™s Option to Purchase Additional ADSsLONDON, UK, 18 July 2016: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or the â€œCompanyâ€), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the closing of the previously announced offering on the NASDAQ Global Market by GW of 2,800,000 of American Depositary Shares (ADSs) and the full exercise by the underwriters of their option to purchase 420,000 additional ADSs from GW at a price of $90.00 per ADS, raising gross proceeds of $289,800,000 (before deducting underwriting discounts, commissions and offering expenses).banner_3GW Pharmaceuticals plc Announces Pricing of U.S. Public Offering of ADSs Raising $252.0 Million on NASDAQ Global MarketLondon, UK, 12 July 2016: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or the â€œCompanyâ€), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the pricing of an underwritten public offering by the Company. GW will issue 2,800,000 of American Depositary Shares (â€œADSsâ€), representing 33,600,000 ordinary shares of GW, at a price to the public of $90.00 per ADS on the NASDAQ Global Market, raising gross proceeds of approximately $252,000,000 (before deducting underwriting discounts, commissions and offering expenses). GW has granted the underwriters a 30-day option to purchase up to an additional 420,000 ADSs at the public offering price less the underwriting discount. Closing of the offering is expected to occur on July 18, 2016.banner_3SativexInformation for patients and medical professionals can be found here...GW ResearchTherapeutic areas of focus, clinical trials andÂ information on EpidiolexÂ Media CentrePress releases, FAQsÂ & contact information for media enquiries...InvestorsShare price, regulatory news, companyÂ presentations and other investor informationThe FDA has granted orphan designation for EpidiolexÂ®Â EpidiolexÂ© is an investigational drug and has not been approved for use by the FDA or any other national regulatory agencyView Press ReleaseMore Information on EpidiolexGWâ€™s lead product, SativexÂ®, is approved in over 20 countries and the company has a highly promising pipeline of additional cannabinoid drug candidates in development.SativexÂ® is approved to treat spasticity (muscle stiffness and spasm) due to Multiple Sclerosis, offering relief to patients for a conditionÂ that previouslyÂ had limited treatment options.GW is recognised as a world leader in cannabinoid science and works closely with a global network of clinicians and scientific collaborators at 25Â academic institutions across the world.Share priceShare chartGW is also researching medicines based upon its validated cannabinoid platform to treat a range of other conditions including pain, cancer, diabetes, and epilepsy.With a commercial product, valuable pipeline, prestigious pharmaceutical partners, diversified business model, and a highly capable in-house team, GW is well placed for growth and value creation.Latest NewsEpidiolexShare Price - NASDAQ:GWPHShare Price - AIM:GWPnews2Introducing GW PharmaceuticalsDiscover more about GW...Meeting patients' needsPatient information can be found here....World leading scienceMore about our scientific collaborations...A valuable pipelineOur areas of therapeutic interest...An exciting futureLearn more about our future opportunities...http://apps.shareholder.com/irxml/irxml.aspx?COMPANYID=AMDA-1TW341&PIN=510645233&FUNCTION=StockQuote&OUTPUT=xml&TICKER=GWPHhttp://ir2.flife.de/data/gwpharma/xml.php
Name: description
Content: news2Introducing GW PharmaceuticalsDiscover more about GW...Meeting patients' needsPatient information can be found here....World leading scienceMore about our scientific collaborations...A valuable ...

Server / Hosting

IP: 185.19.14.34
Latitude: 51.40
Longitude: -0.25
Country: United Kingdom
City: New Malden

Rname

ns2.netnames.net
ns1.netnames.net
relay2.netnames.net
relay1.netnames.net

Target

hostmaster.netnames.net

HTTP Header Response

HTTP/1.1 200 OK Cache-Control: private Content-Length: 18087 Content-Type: text/html; charset=utf-8 Server: Microsoft-IIS/7.5 X-AspNet-Version: 2.0.50727 Date: Sat, 30 Jul 2016 00:16:18 GMT X-Cache: MISS from s_hp65 X-Cache-Lookup: MISS from s_hp65:80 Via: 1.1 s_hp65 (squid/3.5.19) Connection: keep-alive